All In Biotech

Drug Trial Radar · NCT07908524

MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)

MK-2870-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2870-U01 Master Protocol to Evaluate the Safety and Efficacy of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) Alone or in Combination for the Treatment of Participants With Metastatic Castration-Resistant Prostate Cancer/Androgen Pathway Modulator Refractory (mCRPC/APMR)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Jun 29, 2032

Study completion Jun 29, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer/androgen pathway modulator refractory (mCRPC/APMR). Current treatment for mCRPC includes chemotherapy, such as docetaxel. Chemotherapy is medicine that works to destroy cancer cells or stop them from growing. In this trial, researchers want to learn if giving sacituzumab tirumotecan (sac-TMT) alone or with other treatments can treat mCRPC. Sac-TMT is a trial medicine that is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. Opevesostat is another trial medicine designed to block the body from making steroid hormones that cause the cancer cells to grow. The goals of this trial are to learn: * How many participants have the cancer respond (gets smaller or goes away) to the trial treatments * About the safety of the trial treatments and if participants tolerate the treatments. Tolerate means participants will receive the trial treatments unless they need to stop it due to health problems.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • Sacituzumab tirumotecanBiological

    IV infusion

  • Rescue medicationDrug

    Participants receiving sac-TMT may be administered the following rescue medications according to the approved product: granulocyte colony-stimulating factor, histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).

  • DocetaxelDrug

    IV infusion

  • PrednisoneDrug

    Oral administration

  • OpevesostatDrug

    Oral administration

  • Abiraterone acetateDrug

    Oral administration

  • EnzalutamideDrug

    Oral administration

  • PrednisoloneDrug

    Oral administration

  • FludrocortisoneDrug

    Oral administration

  • DexamethasoneDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Phase: Objective Response Rate (ORR)Time frame: Up to approximately 66 months
  2. Efficacy Phase: Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 66 months
  3. Efficacy Phase: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 66 months
  4. Safety Lead-In (Combination Arms Only): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
  5. Safety Lead-In (Combination Arms Only): Number of Participants Who Experience at Least One AETime frame: Up to approximately 66 months
  6. Safety Lead-In (Combination Arms Only): Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 66 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.